Zobrazeno 1 - 10
of 285
pro vyhledávání: '"Exon 19 deletion"'
Publikováno v:
BMC Cancer, Vol 24, Iss 1, Pp 1-13 (2024)
Abstract Purpose Extracellular heat shock protein 90 AA1(eHSP90α) is intricately linked to tumor progression and prognosis. This study aimed to investigate the difference in the value of eHSP90α in post-treatment response assessment and prognosis p
Externí odkaz:
https://doaj.org/article/dee9d7a29eb4463e965a0cdfde0ad8f1
Autor:
Xiaoxuan Li, Xinchi Luan, Mengqi Zhang, Rui Wang, Jing Guo, Jing Lv, Wensheng Qiu, Shufen Zhao
Publikováno v:
Frontiers in Immunology, Vol 15 (2024)
Transformation from non-small cell lung cancer (NSCLC) to small cell lung cancer (SCLC) is rare and is associated with poor prognosis. However, the standard treatment protocols for patients with SCLC transformation remain unknown. Here, we report the
Externí odkaz:
https://doaj.org/article/582b7ebc27f549a9a889f9b3c3668641
Autor:
Tae-Hwan Kim, Jin-Hyuk Choi, Mi Sun Ahn, Hyun Woo Lee, Seok Yun Kang, Yong Won Choi, Young Wha Koh, Seung-Soo Sheen
Publikováno v:
BMC Cancer, Vol 24, Iss 1, Pp 1-10 (2024)
Abstract Background Both first and second-generation EGFR-TKIs are recommended in advanced NSCLC with common EGFR mutations. However, there are few data on the difference in efficacy of EGFR-TKIs based on the type of EGFR mutation and agents. Methods
Externí odkaz:
https://doaj.org/article/1e058ad9026f43c9ab335dd0de4e72b5
Publikováno v:
Cancer Medicine, Vol 13, Iss 8, Pp n/a-n/a (2024)
Abstract Objective To elucidate the potential benefits of combining radiotherapy and epidermal growth factor receptor‐tyrosine kinase inhibitors (EGFR‐TKIs) for individuals with Stage IV lung adenocarcinoma (LUAD) harboring either exon 19 deletio
Externí odkaz:
https://doaj.org/article/fe877c2c322344bda60d0f0b36daf2c9
Publikováno v:
Thoracic Cancer, Vol 14, Iss 31, Pp 3147-3160 (2023)
Abstract Background Clinical significance of various subtypes of epidermal growth factor receptor (EGFR) exon 19 deletion (ex19del) mutation in non‐small cell lung cancer (NSCLC) remains unclear. Methods We analyzed EGFR ex19del subtypes in NSCLC p
Externí odkaz:
https://doaj.org/article/cc41914c3c774dc890a2f2e47fca9aa5
Autor:
Ayaka Saito, Hideki Terai, Tae‐Jung Kim, Katsura Emoto, Ryutaro Kawano, Kohei Nakamura, Hideyuki Hayashi, Hatsuyo Takaoka, Akihiko Ogata, Katsuhito Kinoshita, Fumimaro Ito, Lisa Shigematsu, Masahiko Okada, Takahiro Fukushima, Akifumi Mitsuishi, Taro Shinozaki, Keiko Ohgino, Shinnosuke Ikemura, Hiroyuki Yasuda, Ichiro Kawada, Kenzo Soejima, Hiroshi Nishihara, Koichi Fukunaga
Publikováno v:
Cancer Medicine, Vol 13, Iss 4, Pp n/a-n/a (2024)
Abstract Background Companion diagnostic tests play a crucial role in guiding treatment decisions for patients with non‐small cell lung cancer (NSCLC). The Oncomine Dx Target Test (ODxTT) Multi‐CDx System has emerged as a prominent companion diag
Externí odkaz:
https://doaj.org/article/5439df99e4eb41cfb79841e3ceacf255
Autor:
Kazumi Nishino, MD, PhD, Jin-Yuan Shih, MD, PhD, Kazuhiko Nakagawa, MD, PhD, Martin Reck, MD, PhD, Edward B. Garon, MD, Michelle Carlsen, MS, Tomoko Matsui, Carla Visseren-Grul, MD, Ernest Nadal, MD, PhD
Publikováno v:
JTO Clinical and Research Reports, Vol 5, Iss 2, Pp 100624- (2024)
Introduction: EGFR gene mutations are drivers of NSCLC. The RELAY double-blind, placebo (PBO)-controlled phase 3 study revealed superior progression-free survival (PFS) for ramucirumab plus erlotinib (RAM + ERL) versus PBO (PBO + ERL) in patients wit
Externí odkaz:
https://doaj.org/article/5159d19b07b0438c8a46366db7862e0c
Autor:
Zhiqin Lu, Yali Yi, Linxiao Wang, Yuxi Luo, Daya Luo, Le Xiong, Yun Shu, Hui Luo, Jing Li, Wufu Zhu, Zhimin Zeng, Anwen Liu
Publikováno v:
Translational Oncology, Vol 39, Iss , Pp 101834- (2024)
Background: This study compared the clinical efficacy of first-, second-, and third-generation tyrosine kinase inhibitors (TKIs) in previously untreated non-small cell lung cancer (NSCLC) patients harboring uncommon epidermal growth factor receptor (
Externí odkaz:
https://doaj.org/article/9d9ce6fbad8b48ddbab602bd7b4b158e
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.